HDAC inhibitors restore BRAF inhibitor sensitivity by altering PI3K and survival signaling in melanoma

被引：0
|
作者：
Hersey, Peter [1 ]
Gallagher, Stuart J. [1 ]
机构：
[1] Univ Sydney, Sydney, NSW, Australia
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-3684
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3684
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma
    Irvine, Mal
    Stewart, Ashleigh
    Pedersen, Bernadette
    Boyd, Suzanah
    Kefford, Richard
    Rizos, Helen
    ONCOGENESIS, 2018, 7
  • [32] Imidazopyridazine Inhibitors of PI3Kβ
    Rosse, Gerard
    ACS MEDICINAL CHEMISTRY LETTERS, 2016, 7 (12): : 1012 - 1013
  • [33] Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors
    Rewcastle, Gordon W.
    Kolekar, Sharada
    Buchanan, Christina M.
    Gamage, Swarna A.
    Giddens, Anna C.
    Tsang, Kit Y.
    Kendall, Jackie D.
    Singh, Ripudaman
    Lee, Woo-Jeong
    Smith, Greg C.
    Han, Weiping
    Matthews, David J.
    Denny, William A.
    Shepherd, Peter R.
    Jamieson, Stephen M. F.
    ONCOTARGET, 2017, 8 (29) : 47725 - 47740
  • [34] PI3K inhibitor GDC-0941 synergizes with mTOR inhibitors by blocking negative feedback and causes distinct effects on signaling and apoptosis compared to a dual PI3K/mTOR inhibitor
    Vijapurkar, Ulka
    Robillard, Liliane
    Friedman, Lou S.
    Belvin, Marcia P.
    CANCER RESEARCH, 2010, 70
  • [35] Analysis of BRAF and PI3K mutations in melanoma from UV-exposed workers
    Marconi, Andrea
    Rapisarda, Venerando
    Libra, Massimo
    Proietti, Lidia
    Malaponte, Grazia
    Fenga, Concettina
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2011, 28 : S65 - S65
  • [36] Combination of MEK and PI3K inhibition in BRAF wild-type and mutant melanoma
    Zhang, Yanping
    Peng, Guangyong
    Hsueh, Eddy C.
    CANCER RESEARCH, 2016, 76
  • [37] PI3K Signaling in Neutrophils
    Hawkins, Phillip T.
    Stephens, Len R.
    Suire, Sabine
    Wilson, Michael
    PHOSPHOINOSITIDE 3-KINASE IN HEALTH AND DISEASE, VOL 1, 2010, 346 : 183 - 202
  • [38] CUDC-907, a new dual PI3K and HDAC inhibitor, as ATL therapeutics
    Mori, Naoki
    Ishikawa, Chie
    CANCER SCIENCE, 2018, 109 : 294 - 294
  • [39] Enhancing efficacy of anti-PD-1 antibody by combination with an HDAC/PI3K dual inhibitor in a mouse model of melanoma
    Saijo, Ken
    Imai, Hiroo
    Chikamatsu, Sonoko
    Kasahara, Yuki
    Shirota, Hidekazu
    Katoh, Tadashi
    Ishioka, Chikashi
    CANCER SCIENCE, 2018, 109 : 412 - 412
  • [40] NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
    Serra, Violeta
    Markman, Ben
    Scaltriti, Maurizio
    Eichhorn, Pieter J. A.
    Valero, Vanesa
    Guzman, Marta
    Luisa Botero, Maria
    Llonch, Elisabeth
    Atzori, Francesco
    Di Cosimo, Serena
    Maira, Michel
    Garcia-Echeverria, Carlos
    Lluis Parra, Josep
    Arribas, Joaquin
    Baselga, Jose
    CANCER RESEARCH, 2008, 68 (19) : 8022 - 8030
12345